Praxis’ epilepsy drug cut seizure frequency in mid-stage trialnews2025-08-04T17:50:31+00:00August 4th, 2025|Endpoints News|
Researchers behind Replimune’s melanoma study offer a rare protest of FDA’s CRLnews2025-08-04T17:19:03+00:00August 4th, 2025|Endpoints News|
Royalty market accelerates as XOMA acquires two biotechs and OrbiMed bags another fundnews2025-08-04T15:17:39+00:00August 4th, 2025|Endpoints News|
Thermo Fisher to lay off 85 workers in San Diego County; Lepu Biopharma inks a dealnews2025-08-04T14:35:10+00:00August 4th, 2025|Endpoints News|
Hansa says small trial shows its investigational drug could expand use of Sarepta’s Elevidysnews2025-08-04T11:29:29+00:00August 4th, 2025|Endpoints News|
Biogen is building a ‘ventures’ team to ‘keep early portfolio externalized’news2025-08-04T11:21:17+00:00August 4th, 2025|Endpoints News|
BioNTech sales grow, braces for FDA decision on updated Covid vaccinenews2025-08-04T11:05:41+00:00August 4th, 2025|Endpoints News|
Prasad departs FDA; Merck cuts $3B in costs; Trump renews call for ‘most favored nation’ plan; and morenews2025-08-02T10:00:28+00:00August 2nd, 2025|Endpoints News|
Eating disorder telehealth startup Equip raises $47Mnews2025-08-01T20:25:51+00:00August 1st, 2025|Endpoints News|
Replimune says it’s waiting for FDA on a path forward for rejected cancer treatmentnews2025-08-01T19:33:28+00:00August 1st, 2025|Endpoints News|
